Variables All (n=524) DAPT (n=220) ACT (n=304) P-value P-value
Follow-up available, n (%) 524 (100.0) 220 (100.0) 304 (100.0)
TEE TEE TEE TEE TEE TEE
No. of TEE, n (%) 457 (87.2) 190 (86.4) 267 (87.8) 0.69 0.69
Residual flow, n (%) 33 (6.3) 10 /190 (5.4) 23 /267 (7.6) 0.84 0.84
Significant flow, n (%) 5 (1.0) 2 /190 (1.1) 3 /267 (1.1) >0.99 >0.99
DRT, n (%) 18 (3.4) 5 /190 (2.6) 13/267 (4.9) 0.63 0.63
Anti-thrombotic therapy at the time of follow-up Anti-thrombotic therapy at the time of follow-up Anti-thrombotic therapy at the time of follow-up Anti-thrombotic therapy at the time of follow-up Anti-thrombotic therapy at the time of follow-up Anti-thrombotic therapy at the time of follow-up
Any anticoagulation, n (%) 31 (5.9) 14 (6.4) 17 (5.6) 0.71 0.71
Vitamin K antagonists, n (%) 4 (0.7) 2 (0.9) 2 (0.7) >0.99 >0.99
Non-vitamin K antagonists, n (%) 27 (5.2) 12 (5.5) 15 (4.9) 0.84 0.84
Single anti-platelet, n (%) 464 (88.5) 188 (85.5) 276 (90.8) 0.07 0.07
Dual anti-platelet, n (%) 19 (3.6) 9 (4.1) 10 (3.3) 0.64 0.64
Anticoagulant plus anti-platelet, n (%) 0 (0.0) 0 (0.0) 0 (0.0) >0.99 >0.99
No anti-thrombus therapy, n (%) 10 (1.9) 9 (4.1) 1 (0.3) <0.01 <0.01
Clinical events outcome Clinical events outcome Clinical events outcome Clinical events outcome Clinical events outcome Clinical events outcome
All DAPT ACT HR (95% CI)# P-value*
n =524 n =220 n =304
Primary efficacy outcome 40 (7.6) 21 (9.5) 19 (6.3) 1.58 (0.84–2.97) 0.14
Primary safety outcome 28 (5.3) 10 (4.5) 18 (5.9) 0.80 (0.38–1.69) 0.57
Net clinical benefit, n (%) 66 (12.6) 30 (13.6) 36 (11.8) 1.23 (0.75–2.02) 0.39
Death Death Death Death Death Death
All-cause death, n (%) 45 (8.6) 26 (11.8) 19 (6.3) 1.97 (1.09–3.58) 0.02
Cardiovascular/Unexplained death, n (%) 23 (4.4) 14 (6.4) 9 (3.0) 2.24 (0.98–5.14) 0.05
Non-cardiovascular death, n (%) 22 (4.2) 12 (5.4) 10 (3.3) 1.74 (0.74–4.05) 0.19
Ischemic stroke/tia/se Ischemic stroke/tia/se Ischemic stroke/tia/se Ischemic stroke/tia/se Ischemic stroke/tia/se Ischemic stroke/tia/se
Ischemic stroke/TIA/SE, n (%) 18 (3.4) 7 (3.2) 11 (3.6) 0.94 (0.37–2.41) 0.90
Ischemic stroke, n (%) 13 (2.5) 5 (2.3) 8 (2.6) 0.92 (0.30–2.78) 0.88
Disabling stroke, n (%) 7 (1.3) 3 (1.4) 4 (1.3) 1.10 (0.24–4.96) 0.90
Non-disabling stroke, n (%) 6 (1.1) 2 (0.9) 4 (1.3) 0.74 (0.14–3.76) 0.72
TIA, n (%) 5 (1.0) 2 (0.9) 3 (1.0) 0.98 (0.16–5.86) 0.98
SE, n (%) 0 (0.0) 0 (0.0) 0 (0.0) - >0.99
Bleedings Bleedings Bleedings Bleedings Bleedings Bleedings
Any bleeding 62 (11.8) 17 (7.7) 45 (14.8) 0.53 (0.32–0.88) 0.02
Major bleeding, n (%) 28 (5.3) 10 (4.5) 18 (5.9) 0.80 (0.38–1.69) 0.57
Intracranial, n (%) 3 (0.5) 0 (0.0) 3 (1.0) - 0.15
Gastrointestinal, n (%) 19 (3.6) 7 (3.2) 12 (4.0) 0.84 (0.34–2.09) 0.70
Other sites, n (%) 6 (1.1) 3 (1.4) 3 (1.0) 1.45 (0.28–7.39) 0.65
CRNMB, n (%) 34 (6.5) 7 (3.2) 27 (8.9) 0.37 (0.19–0.73) 0.01